News tagged with her2
Turning off cancer's growth signals
One hallmark of cancer cells is uncontrollable growth, provoked by inappropriate signals that instruct the cells to keep dividing. Researchers at MIT and Brigham and Women’s Hospital have now identified ...
Jun 13, 2011 |
4.2 / 5 (6) |
2
|
Tracking therapeutic nanoparticles that target breast tumors
Researchers at Rice University, collaborating with investigators at the Baylor College of Medicine, have used two different types of imaging technologies to track the delivery of a therapeutic nanoparticle to breast tumors. ...
Nanotechnology / Bio & Medicine
Dec 17, 2010 |
5 / 5 (2) |
0
|
Combination overcomes breast cancer resistance to herceptin
Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson ...
Mar 13, 2011 |
4 / 5 (2) |
0
|
Risk of aggressive breast cancer subtype three times higher for black women
Lifestyle, age and weight have all been considered as risk factors for breast cancer. Now a study published in the open access journal Breast Cancer Research has found that even taking these factors into consideration, black ...
Mar 25, 2009 |
5 / 5 (1) |
2
New radiation-free targeted therapy detects and eliminates breast cancer tumors in mice
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, ...
Mar 30, 2009 |
5 / 5 (1) |
0
Combining nanotubes and antibodies for breast cancer 'search and destroy' missions
cylinders of carbon about a nanometer in diameter -- have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for ...
Dec 02, 2009 |
5 / 5 (1) |
0
Targeted therapy prolongs life in patients with HER2-positive breast cancer
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine ...
Dec 11, 2009 |
5 / 5 (1) |
0
Antibody-guided drug shows encouraging activity in metastatic breast cancer
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from ...
Dec 12, 2009 |
5 / 5 (1) |
0
I-SPY 2 study speeds up treatment for breast cancer
A clinical trial that aims to speed up the study of new treatments for certain subtypes of breast cancer now has a designated study site at the Diane O'Connor Thompson Breast Center at the University of Colorado Hospital.
Nov 19, 2010 |
5 / 5 (1) |
0
Researchers use light to measure cancer cells' response to treatment
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon ...
Dec 20, 2011 |
5 / 5 (1) |
0
HER2/neu
HER2/neu (also known as ErbB-2) stands for "Human Epidermal growth factor Receptor 2" and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2/neu has also been designated as CD340 (cluster of differentiation 340) and p185. It is encoded by the ERBB2 gene.
For more information about HER2/neu, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
